Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Ceftazidim

Klassificering: A

Preparat: Ceftazidim Actavis, Ceftazidim Eberth, Ceftazidim Sandoz, Fortum, Fortum®

ATC kod: J01DD02

Substanser: ceftazidim, ceftazidimpentahydrat

Sammanfattning

Hos patienter med samhällsförvärvad pneumoni har effekten av ceftazidim visats vara likvärdig hos kvinnor och män.
 
Vår bedömning är att de beskrivna skillnaderna inte motiverar olika dosering eller behandling hos kvinnor och män.

Additional information

Pharmacokinetics and dosing

The pharmacokinetics of ceftazidime was assessed in healthy volunteers (12 men, 12 women) receiving 1 g ceftazidime as bolus i.v. injection. Volume of distribution was 17% lower in women. Eight men and eight women also received 1 g ceftazidime i.m. injection. Compared to men, women had 38% higher volume of distribution, 25% lower AUC, higher Cmax and longer Tmax [2]. Also a study in burn patients found that the volume of distribution was higher in women (20%) [3].In an Ethiopian study assessing appropriate dosage adjustments were made in hospitalized patients with renal impairment (40 men, 33 women), Multivariate analysis showed that there were no difference between men and women in the proportion of appropriately adjusted prescription entries per patient [4].

During pregnancy, renal clearance of ceftazidime has been shown to be higher, 39% during first trimester and 65 % during third trimester, than post-partum. The authors suggest that the dosage of ceftazidime should be increased in pregnancy by approximately 40% [5].

Effects

The clinical and bacteriological responses to ceftazidime (1 g every 8 h) versus meropenem (0.5 g every 8 h) were assessed in hospitalized patients (257 men, 152 women) with community-acquired pneumonia, according to risk factors. The responses were similar in men and women in both treatment groups [1].

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of ceftazidime have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Försäljning på recept

Läkemedel innehållande ceftazidim (ATC-kod J01DD02) används huvudsakligen på sjukhus och därför saknas könsspecifika användningsdata [6].

Uppdaterat: 2019-02-26

Litteratursökningsdatum: 2016-08-16

Referenser

  1. Finch RG, Pemberton K, Gildon KM. Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime. J Chemother. 1998;10:35-46. PubMed
  2. Sommers DK, Walters L, Van Wyk M, Harding SM, Paton AM, Ayrton J. Pharmacokinetics of ceftazidime in male and female volunteers. Antimicrob Agents Chemother. 1983;23:892-6. PubMed
  3. Conil JM, Georges B, Lavit M, Laguerre J, Samii K, Houin G et al. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation. Br J Clin Pharmacol. 2007;64:27-35. PubMed
  4. Getachew H, Tadesse Y, Shibeshi W. Drug dosage adjustment in hospitalized patients with renal impairment at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. BMC Nephrol. 2015;16:158. PubMed
  5. Nathorst-Böös J, Philipson A, Hedman A, Arvisson A. Renal elimination of ceftazidime during pregnancy. Am J Obstet Gynecol. 1995;172:163-6. PubMed
  6. Concise. Stockholm: eHälsomyndigheten. 2015 [cited 2016-08-22.] länk

Författare: Linnéa Karlsson Lind

Faktagranskat av: Mia von Euler

Godkänt av: Karin Schenck-Gustafsson